research use only

Atamparib (RBN-2397) PARP inhibitor

Name: Atamparib (RBN-2397)
Brand: Selleck Chemicals
SKU: S8993
Availability: InStock
Rating: 5 (3 reviews)

Cat.No.S8993

RBN-2397 (Atamparib) is a potent, selective and orally active NAD+ competitive inhibitor PARP7 with IC50 of <3 nM and Kd of <0.001 μM. This compound has the potential for the research of tumor treatment.

Chemical Structure

Molecular Weight: 523.43

Jump to

Quality Control

Batch: Purity: 99.80%

99.80

Related Targets	HDAC ATM/ATR DNA-PK WRN DNA/RNA Synthesis Topoisomerase PPAR Sirtuin Casein Kinase eIF
Other PARP Inhibitors	XAV-939 AZD5305 (Saruparib) Veliparib (ABT-888) PJ34 HCl AG-14361 Iniparib (BSI-201) G007-LK UPF 1069 A-966492 Pamiparib

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (191.04 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 13 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	5.000mg/ml (9.55mM)	Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to make it clear; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	523.43	Formula	C₂₀H₂₃F₆N₇O₃	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	2381037-82-5	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N/A			SMILES	CC(COCCC(=O)N1CCN(CC1)C2=NC=C(C=N2)C(F)(F)F)NC3=C(C(=O)NN=C3)C(F)(F)F

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC₅₀/Ki	PARP7 (Cell-free assay) <0.001 μM(Kd) PARP7 (Cell-free assay) <3 nM
In vitro	Atamparib (RBN-2397) restores cytosolic nucleic acid sensing and blocks cell proliferation in a human lung cancer cell line.
In vivo	Atamparib (RBN-2397) causes complete regressions in human NSCLC NCI-H1373 xenografts and dose-dependent pharmacodynamic effects. It also induces tumor-specific adaptive immune memory in CT26 syngeneic model with durable complete responses.
References	[1] https://ribontx.com/wp-content/uploads/2020/04/MVasbinder_FINAL.pdf

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-07-29)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07374419	RECRUITING	NSCLC Adenocarcinoma; Solid Tumor	Nerviano Medical Sciences (Shanghai) Ltd.	2026-03-18	PHASE1; PHASE2
NCT05127590	UNKNOWN	Advanced Squamous Non-Small Cell Lung Carcinoma	Ribon Therapeutics, Inc.	2022-03-15	PHASE1; PHASE2
NCT04053673	UNKNOWN	Solid Tumor, Adult	Ribon Therapeutics, Inc.	2019-08-01	PHASE1
NCT05127590	Active not recruiting	Advanced Squamous Non-Small Cell Lung Carcinoma	Ribon Therapeutics Inc.	2022-03-15	Phase 1\|Phase 2
NCT04053673	Recruiting	Solid Tumor Adult	Ribon Therapeutics Inc.	2019-08-01	Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):